Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.71 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | PRNP | P04156 | 1/20 | 0.47 |
| ▸ | MAT2A | P31153 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1289759 | 0.84 | SCN9A (1.00) | SCN9A | |
| SCHEMBL20610507 | 0.83 | KMT2A (0.59) | SCN9AMEN1KMT2AMAPTGAA | |
| SCHEMBL28872949 | 0.83 | SCN9A (0.52) | SCN9ANUDT1ADORA2AMEN1KMT2A | |
| SCHEMBL28023475 | 0.82 | PDE5A (0.59) | SCN9ANUDT1ADORA2AMEN1KMT2A | |
| SCHEMBL10674090 | 0.81 | NPC1 (0.54) | SCN9AALDH1A1HPGD | |
| SCHEMBL26314588 | 0.81 | PRNP (0.67) | SCN9ANUDT1ADORA2AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28023495 | 0.81 | PDE5A (0.57) | SCN9ANUDT1ADORA2AMEN1KMT2A | |
| SCHEMBL27627952 | 0.79 | SCN9A (0.51) | SCN9ANUDT1MEN1KMT2AMAPT | |
| SCHEMBL14964747 | 0.78 | KMT2A (0.55) | SCN9AMEN1KMT2AMAPTELANE | |
| SCHEMBL3520696 | 0.78 | SCN9A (0.48) | SCN9AMEN1KMT2APRNPMAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810596-A1 | QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210078990-A1 | TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-10851093-B2 | Tyrosine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851093-B2 | Tyrosine kinase inhibitors | TYRO3, RET, AXL | SCN9A 2061/4885NUDT1 1757/4885ADORA2A 385/4885 |
| US-20210078990-A1 | TYROSINE KINASE INHIBITORS | TYRO3, RET, AXL | SCN9A 2061/4885NUDT1 1757/4885ADORA2A 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.